Please login to the form below

Not currently logged in

Teva fights off Novartis to market generic famciclovir tablets

Teva wins favourable ruling against Novartis for a preliminary injunction related to the Israeli firm's famciclovir treatment for genital herpes

Israeli-based Teva has received a favourable ruling from the US District Court for the District of New Jersey regarding a lawsuit filed by Swiss pharmaceutical company Novartis for a preliminary injunction related to Teva's famciclovir, a generic version of Novartis' Famvir treatment for genital herpes.

Teva's ANDA to market famciclovir tablets in 125 mg, 250 mg and 500 mg has already been granted final approval by the FDA.

Famvir had annual sales of approximately USD 200m in the US for the twelve months to 30 June 2007, based on IMS data. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity, which will begin from the date of first commercial marketing.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has yet to be set.

7th September 2007


Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...